at Fox Business (Mar 21, 2013)
Unlike many pharmaceutical deals, which often deliver little, if any, value as anticipated new...
Unlike many pharmaceutical deals, which often deliver little, if any, value as anticipated new treatments fail to materialize, Glaxo's (GSX) Stiefel acquisition looks likely to make money for shareholders. GSK -1.7%.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs